Literature DB >> 7216550

Clinical study on the hypotensive effect of diltiazem hydrochloride.

K Maeda, T Takasugi, Y Tsukano, Y Tanaka, K Shiota.   

Abstract

Diltiazem HCl was administered p.o. at a fixed daily dose level of 180 mg to patients with essential hypertension, and the hypotensive effect of the drug was investigated. The following results were obtained: diltiazem HCl given alone exhibited a hypotensive effect on systolic pressure in 88.9% of the patients and on diastolic pressure in 66.7% of the patients. The concurrent use of diltiazem HCl with trichlormethiazide exerted a hypotensive effect on patients who were nonresponsive to diltiazem HCl alone. As regards side effects, one patient complained of gastric fullness and one of dizziness. However, the symptoms were so mild that further continuation of diltiazem HCl therapy was possible. From the results obtained, it is concluded that diltiazem HCl can effectively be used clinically as a hypotensive drug.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7216550

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  5 in total

1.  Long-acting nifedipine versus metoprolol as monotherapy for essential hypertension. A randomized, controlled crossover study.

Authors:  K S Woo; C O Pun
Journal:  West J Med       Date:  1990-02

Review 2.  Diltiazem.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1985-01

Review 3.  Calcium antagonists. Clinical use in the treatment of systemic hypertension.

Authors:  C Spivack; S Ocken; W H Frishman
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

Review 4.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

5.  Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 MG) after repeated administration in healthy volunteers.

Authors:  G Bianchetti; C Dubruc; V Sultana; G Houin; P Rosenzweig
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.